Clinical trials
Lung cancer clinical trials
Cancer that begins in the lungs, often linked to smoking but also affecting non-smokers. We’re tracking 2,012 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05450965RecruitingPhase 2
Onvansertib for relapsed small cell lung cancer
This trial studies onvansertib, a targeted medicine, in people whose small cell lung cancer has come back or did not respond to prior platinum chemotherapy. It aims to shrink tumors and improve outcomes after standard treatment has already been tried.
Baltimore, MarylandAges 18 years+ - NCT05452005RecruitingPhase 1
PET scan with a new tracer for lung cancer brain metastases
This Phase 1 study tests whether a specialized PET scan tracer can “light up” metastatic non-small cell lung cancer in the brain. If you join, you’ll get brain MRI and PET/CT scans and you’ll continue with your planned cancer treatments and follow-up imaging.
Sacramento, CaliforniaAges 18 years+ - NCT05477979Recruiting
Study how stress affects lung cancer treatment outcomes
This study looks at whether psychological stress changes how well lung cancer treatments work and what the outlook is. You may qualify if you’re about to start (or recently started) certain immunotherapy-based treatments, and you can complete stress and well-being questionnaires.
Changsha, HunanAges 18 years+ - NCT05483491RecruitingPhase 1
TCR cell therapy for select metastatic cancers
This Phase 1 trial tests a personalized immune-cell treatment (TCR-T cells) for certain metastatic cancers. It targets cancers that carry a specific marker and requires patients to have a specific immune-system match, aiming to improve cancer control when standard options were already tried.
New Brunswick, New JerseyAges 18 years+ - NCT05493566RecruitingEarly Phase 1
Low-dose IL-2 plus pembrolizumab for stage IV lung cancer
This early-phase study tests whether low-dose IL-2 combined with pembrolizumab can help treat stage IV non-small cell lung cancer that has not had prior advanced treatment. It may be an option if your tumor has certain immune-marker findings (PD-L1) and you meet safety requirements.
Atlanta, GeorgiaAges 18 years+ - NCT05501665RecruitingPhase 1/Phase 2
Adaptive radiation plus pembrolizumab for stage IV lung cancer
This trial tests a personalized (“adaptive”) radiation plan combined with pembrolizumab, and possibly chemotherapy, for advanced stage IV lung cancer. It aims to improve cancer control while carefully managing side effects, including in patients with certain brain metastases.
Nashville, TennesseeAges 18 years+ - NCT05502523Recruiting
Blood test DNA levels after lung surgery
This study looks at how different lung surgical techniques affect levels of tumor DNA in the blood before and after surgery for early-stage lung cancer. It may help doctors choose surgical approaches and use a blood test to monitor cancer after surgery.
Abington, PennsylvaniaAges 18 years+ - NCT05537922Recruiting
Study uses data to tailor lung cancer care with immunotherapy
This study collects and analyzes medical information (and sometimes tissue samples) to help personalize treatment plans for advanced non-small-cell lung cancer using immunotherapy. It may help researchers find which people benefit most and how treatment can be better matched to each patient.
Chicago, IllinoisAges 18 years+ - NCT05541744Recruiting
Using tumor gene data to help guide care for lung cancer
This study looks at gene-related information from a lung tumor sample and pairs it with special imaging to better understand non-small cell lung cancer. If you have a confirmed diagnosis and the right samples/tests, this may help researchers match patients to the most useful information for planning treatment.
Hualien CityAges 20 years+ - NCT05550961Recruiting
Real-world study of innovative treatments for lung cancer
This study collects real-world information about people with lung cancer who get newer kinds of cancer drugs. It aims to understand how these innovative therapies work in everyday care and help future research.
MilanAges 18 years+ - NCT05557474Recruiting
Test of a lung cancer prognosis kit after early tumor removal
This study tests a lab “prognosis kit” to better predict how early-stage lung cancer may progress after the tumor has been fully removed. You may be asked to provide tumor samples and possibly blood/body fluid samples so researchers can validate the kit.
Taichung, TaiwanAges 20 years+ - NCT05570825RecruitingPhase 2
Study drug SX-682 with pembrolizumab for advanced lung cancer
This trial tests SX-682 plus pembrolizumab (an immunotherapy) to treat metastatic or recurrent non-small cell lung cancer (NSCLC). It aims to see how well the combination works and whether it can shrink or control the cancer in people whose tumors have enough PD-L1.
Seattle, WashingtonAges 18 years+ - NCT05572944Recruiting
Using family risk to predict lung cancer in never-smokers
This study builds and tests risk prediction tools for lung cancer in people who have never smoked, using information from family history. If it works, it may help doctors identify who might need closer screening earlier.
Taichung, TaiwanAges 20–80 - NCT05607108RecruitingPhase 2
Study drug for advanced lung cancer with a specific genetic change
This Phase 2 trial tests ZEN003694 in people with squamous (a type of) lung cancer that has returned or spread. It’s designed for tumors that have a certain gene change, and it may offer a new treatment option after prior chemotherapy and immunotherapy.
Basking Ridge, New JerseyAges 18 years+ - NCT05611034RecruitingPhase 1
Testing a lung treatment for colorectal cancer spread to lungs
This Phase 1 trial tests a targeted treatment delivered to the lungs for colorectal cancer that has spread to the lungs. It aims to see if the approach is safe and can reach lung tumors, especially when there are multiple lung lesions.
Toronto, OntarioAges 18–70 - NCT05620342RecruitingEarly Phase 1
CAR T-cell therapy for GD2-positive lung cancer
This early-phase study tests a customized immune-cell treatment (CAR T cells) that targets a protein called GD2 on lung cancer cells. It may help people with certain lung cancers that did not respond to platinum chemotherapy and who have also had treatment that blocks PD-1/PD-L1.
Chapel Hill, North CarolinaAges 18 years+ - NCT05624996RecruitingPhase 3
Targeted high-dose radiation added to standard lung cancer treatment
This trial tests whether adding high-dose, targeted radiation to the usual treatment helps people with locally advanced, non-operable lung cancer live longer or better control the cancer. It may help shrink tumors in the chest and improve outcomes when surgery can’t be done.
Birmingham, AlabamaAges 18 years+ - NCT05632913Recruiting
Radiation seeds trial for recurring lung cancer in the chest
This trial tests a treatment that places tiny radiation “seeds” inside/near the chest tumor to treat recurrent lung cancer. It may help people whose cancer has come back and can be safely reached by the radiation device.
JerusalemAges 18 years+ - NCT05657873RecruitingPhase 2
Targeted radiation for metastatic lung cancer with liver spread
This trial studies whether adding targeted radiation to the liver (small-area, high-precision radiation) can help people with stage IV non-small cell lung cancer. Participants also start standard “anti–PD-1/PD-L1” immunotherapy (with chemotherapy in some cases).
Miami, FloridaAges 18 years+ - NCT05671887Recruiting
Double lung transplant registry for certain lung-limited cancers
This study follows people who are getting a double lung transplant and have specific lung-only (or lung-limited) cancer or other serious lung conditions. It’s an observational registry, meaning it collects real-world information to learn which patients may benefit from transplant and how they do afterward.
Chicago, IllinoisAges 18–75 - NCT05681780RecruitingPhase 1
CD40L-treated immune cells for advanced lung cancer with certain gene changes
This Phase 1 study tests a lab-made immune cell treatment (TIL) boosted with CD40L, plus nivolumab, for stage IV or returning non-small cell lung cancer with specific gene changes (EGFR, ALK, ROS1, or HER2). It aims to help your immune system attack the cancer after it has grown despite standard treatments.
Tampa, FloridaAges 18 years+ - NCT05696782RecruitingPhase 2
Durvalumab after chemoradiation for stage III lung cancer
This trial tests giving durvalumab (an immune therapy) soon after standard chemotherapy and radiation for stage II–III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this “quick start” approach improves outcomes compared with waiting longer to begin durvalumab.
Winston-Salem, North CarolinaAges 18 years+ - NCT05699213Recruiting
MRI and blood tests for lung nodules found on screening
This study looks at whether MRI scans and blood-related biomarkers can help better understand lung nodules found during routine lung cancer screening. It may help doctors decide which nodules need closer follow-up versus less intensive monitoring.
Los Angeles, CaliforniaAges 50 years+ - NCT05733000RecruitingPhase 2
CPI-613 plus hydroxychloroquine with chemo for advanced solid tumors
This trial tests a drug called CPI-613 (devimistat) combined with hydroxychloroquine along with either 5-fluorouracil or gemcitabine chemo. It’s for people with advanced cancers that have stopped responding to standard treatments, aiming to shrink tumors and slow cancer growth.
Chicago, IllinoisAges 18 years+
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer?
- Yes. Clin2 currently lists 2,012 recruiting lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.